Table 3.
Hazard ratios for overall survival in stage III and IV biliary cancer patients receiving ACT or not according to TIN
| Patient cohort | Factor | Patients | ACT (yes vs no) | ||
|---|---|---|---|---|---|
| Number | % | Hazard ratio (95% CI) | P‐value | ||
| Training set | TIN | 75 | 0.480(0.275‐0.839) | .016 | |
| Low TIN | 33 | 44.0 | 0.294(0.099‐0.873) | .047 | |
| High TIN | 42 | 56.0 | 0.749(0.383‐1.466) | .415 | |
| Validation set | TIN | 48 | 0.646(0.316‐1.322) | .205 | |
| Low TIN | 15 | 31.3 | 0.100(0.022‐0.462) | .006 | |
| High TIN | 33 | 68.8 | 1.148(0.519‐2.536) | 0.735 | |
| Combined set | TIN | 123 | 0.574(0.373‐0.883) | .012 | |
| Low TIN | 48 | 39.0 | 0.216(0.090‐0.520) | .002 | |
| High TIN | 75 | 61.0 | 0.863(0.527‐1.415) | .556 | |
P < .05 is considered statistically significant (bold).
Combined set was generated by combing the training and validation sets together.
ACT, adjuvant chemotherapy; TIN, tumor infiltrating neutrophil.